NO-aspirin: mechanism of action and gastrointestinal safety (Q28196651)

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Cyclo-oxygenase isoenzymes. Structural basis for selective inhibition of cyclo-oxygenases by anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Acetylation of prostaglandin synthase by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

1 reference

7 January 2021

Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

A diclofenac derivative without ulcerogenic properties

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Gastrointestinal-sparing anti-inflammatory drugs: The development of nitric oxide-releasing NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitric oxide in mucosal defense: a little goes a long way.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

NO-aspirin protects from T cell–mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Potential cardioprotective actions of no-releasing aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitric oxide-releasing NSAIDs: a review of their current status

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitrosylation. the prototypic redox-based signaling mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Apoptosis-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Cytokine-processing enzymes. Stopping the cuts

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Caspases: enemies within

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

IL-1 and IL-18 receptors, and their extended family.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

NO-releasing NSAIDs are caspase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Does nitric oxide modulate mitochondrial energy generation and apoptosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Vascular protective actions of a nitric oxide aspirin analog in both in vitro and in vivo models of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Nitric oxide inhibits iron-induced lipid peroxidation in HL-60 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

The effect of aspirin and two nitric oxide donors on the infarcted heart in situ

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021

NCX4016: a novel antithrombotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900047-1

7 January 2021